Experimental drug targets dangerous blood fats in early safety trial
NCT ID NCT03783377
Summary
This early-stage study tested the safety and effects of a new drug called ARO-APOC3. It involved 112 healthy volunteers and patients with very high triglyceride levels or a rare genetic condition that causes severe fat buildup in the blood. The main goal was to see how the body handles the drug and if it is safe for people.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 10
Papatoetoe, Auckland, 2025, New Zealand
-
Research Site 11
Christchurch, 8011, New Zealand
-
Research Site 2
Camperdown, New South Wales, 2050, Australia
-
Research Site 3
Adelaide, South Australia, 5000, Australia
-
Research Site 4
Perth, Washington, 6009, Australia
-
Research Site 5
Sippy Downs, Queensland, Australia
-
Research Site 6
Chicoutimi, Quebec, G7H 7K9, Canada
-
Research Site 7
London, Ontario, N6A 5B7, Canada
-
Research Site 8
Montreal, Quebec, H2W 1R7, Canada
-
Research Site 9
Grafton, Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.